New and experimental HIV treatments: latest news

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

  • Two new doravirine pills approved in US

    The US Food and Drug Administration (FDA) has approved two new products containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine. These products are also under review by the European Medicines Agency.Produced by Merck/MSD, Pifeltro is a stand-alone doravirine tablet that ...

    12 September 2018 | Liz Highleyman
  • Doravirine maintains higher rate of virological suppression over darunavir/ritonavir though 96 weeks of follow-up

    The experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine was more effective than darunavir/ritonavir over nearly two years of follow-up, according to results of a phase 3 study presented to the 22nd International AIDS Conference (AIDS 2018) ...

    30 July 2018 | Michael Carter
  • The kick that didn’t kill: first-ever randomised HIV cure study fails to eliminate infected cells

    One study whose results were eagerly awaited at the 22nd International AIDS Conference (AIDS 2018) was the RIVER study. This was the first study to add to standard HIV therapy a vaccine-plus-drug regimen intended to reduce ...

    26 July 2018 | Gus Cairns
  • Dolutegravir dual therapy works well for first-time HIV treatment

    A two-drug combination of dolutegravir (Tivicay) and lamivudine suppressed viral load as well as a standard three-drug antiretroviral regimen for people with HIV starting treatment for the first time, according to results from the GEMINI studies presented yesterday at the 22nd International ...

    25 July 2018 | Liz Highleyman
  • TAF only superior to TDF when used with a boosting agent

    The benefits of tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) may have been overstated, according to the results of a meta-analysis published in the Journal of Virus Eradication. It was only when used in an ...

    10 April 2018 | Michael Carter
  • Powerful new PrEP and treatment drug should be effective as a small weekly pill

    MK-8591 or EFdA is a novel and exceptionally long-lasting and potent HIV drug, being developed by Merck. It is a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Its potency and longevity are due to the fact that ...

    12 March 2018 | Gus Cairns
  • Ibalizumab, active against highly resistant HIV, now approved in US

    Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, is active against virus strains that have developed resistance to multiple other antiretrovirals, according to a poster presentation at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) ...

    08 March 2018 | Liz Highleyman
  • Biktarvy combo maintains viral suppression after switching therapy

    People who switched to a single-tablet regimen containing the integrase inhibitor bictegravir were as likely to maintain an undetectable viral load as those who stayed on their current suppressive regimen containing dolutegravir, according to a presentation at the 25th ...

    07 March 2018 | Liz Highleyman
  • Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys

    Treatment with a broadly neutralising antibody plus an immune-stimulating drug led to long-term viral remission after interrupting antiretroviral therapy in a monkey study, according to data presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) this week ...

    05 March 2018 | Liz Highleyman
  • US regulators approve new HIV combo pill containing bictegravir

    The US Food and Drug Administration (FDA) yesterday approved Biktarvy, Gilead Sciences' new single tablet antiretroviral regimen containing the HIV integrase inhibitor bictegravir, which was highly effective and well tolerated in clinical trials. Biktarvy is the first fixed-dose combination ...

    08 February 2018 | Liz Highleyman
More news

New and experimental HIV treatments news selected from other sources

More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.